Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators

Fredrik Schjesvold, Heinz Ludwig, María-Victoria Mateos, Haifaa Abdulhaq, Stefan Norin, Marcus Thuresson, Nicolaas A. Bakker, Paul G. Richardson, Pieter Sonneveld

Blood (2022) 140 (Supplement 1): 12607–12609.

https://doi.org/10.1182/blood-2022-160159

Published: 2022

Journal Articles

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Enrique M. Ocio, MDPhD, Yvonne A. Efebera, MD MPH, Roman Hájek, MD PhD, Miquel Granell, MD, Vladimir Maisnar, MD, Jan Straub, MD, Jean-Richard Eveillard, MD, Lionel Karlin, MD, Vincent Ribrag, MD, María-Victoria Mateos, MD PhD, Albert Oriol, Malin Sydvander, MSc, Stefan Norin, MD, Sofia Mannikko, MSc, Luděk Pour, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-135991

Published: 2020

Journal Articles

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Enrique M. Ocio, Yvonne A. Efebera, MD MPH, Miquel Granell, MD, Roman Hajek, MD, Vladimir Maisnar, MD, Lionel Karlin, MD, María-Victoria Mateos, MD PhD, Paul G. Richardson, MD, Albert Oriol, MD, Stefan Norin, MD, Malin Sydvander, MSc, Jakob Obermüller, MSc, Luděk Pour, MD

Blood (2019) 134 (Supplement_1): 3124.

https://doi.org/10.1182/blood-2019-124815

Published: 2019

Journal Articles

5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C

Aniket Bankar, MBBS, MD DM, Thirushi Piyumika Siriwardena, Biljana Rizoska, PhD, Christina Rydergård, BSc, Helen Kylefjord, BSc, Vilma Rraklli, PhD, Anders Eneroth, PhD, Pedro Pinho, PhD, Stefan Norin, MD PhD, Johan Bylund, PhD, Sara Moses, PhD, Richard Bethell, PhD, Simon Kavanagh, MBBS(Hons), FRACP, FRCPA, Xiaoming Wang, Rose Hurren, BSc, Mark D. Minden, MD PhD, Paul Targett-Adams, PhD BSc, Aaron D Schimmer, MD PhD, Mark Albertella, PhD

Blood (2018) 132 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2018-99-114345

Published: 2018

Journal Articles

Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia

Pedro Pinho, PhD, Helen Kylefjord, BSc, Vilma Rraklli, PhD, Christina Rydergård, BSc, Biljana Rizoska, PhD, Anders Eneroth, PhD, Johan Bylund, PhD, Sara Moses, PhD, Stefan Norin, MD PhD, Richard Bethell, PhD, Aniket Bankar, MBBS, MD DM, Thirushi Piyumika Siriwardena, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Mark Albertella, PhD, Paul Targett-Adams, PhD BSc

Blood (2018) 132 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2018-99-114440

Published: 2018

Journal Articles

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Sandra Eketorp Sylvan, MD PhD, Anna Asklid, MD, Hemming Johansson, Jenny Klintman, MD PhD, Jenny Bjellvi, MD, Staffan Tolvgård, MD, Eva Kimby, Stefan Norin, MD PhD, P-O Andersson, MD PhD Prof., Claes Karlsson, MD PhD, Karin Karlsson, MD, Birgitta Lauri, MD, Mattias Mattsson, MD, Anna Bergendahl Sandstedt, MD, Maria Strandberg, MD, Anders Österborg, MD PhD Prof., Lotta Hansson

Blood (2017) 130 (Supplement 1): 1744.

https://doi.org/10.1182/blood.V130.Suppl_1.1744.1744

Published: 2017

Journal Articles

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Maria Winqvist, MSc, MD, Per-Ola Andersson, MD PhD, Anna Asklid, MD, Karin Karlsson, MD, Claes Karlsson, MD PhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD Assoc Prof, Mattias Mattsson, MD, Stefan Norin, MD PhD, Anna Bergendahl Sandstedt, MD, Lotta Hansson, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 5353.

https://doi.org/10.1182/blood.V130.Suppl_1.5353.5353

Published: 2017

Journal Articles

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Lotta Hansson, MD PhD, Maria Winqvist, MD, Anna Asklid, MD, P-O Andersson, MDPhD, Karin Karlsson, MD, Claes Karlsson, MDPhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD, Mattias Mattsson, MD, Stefan Norin, MDPhD, Anna Sandstedt, MD, Anders Österborg, MDPhD

Blood (2015) 126 (23): 1745.

https://doi.org/10.1182/blood.V126.23.1745.1745

Published: 2015

Journal Articles

A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study

Blood (2013) 122 (21): 1645.

https://doi.org/10.1182/blood.V122.21.1645.1645

Published: 2013

Journal Articles

Cytogenetic Abnormalities In the Spleen In CLL Patients.

Stefan Norin, MD, Ann Wallblom, Mohit Aggarwal, Birgitta Sander, MD, Eva Kimby

Blood (2010) 116 (21): 4618.

https://doi.org/10.1182/blood.V116.21.4618.4618

Published: 2010

Journal Articles

Clonal Evolution During Long-Term Follow-up Using Fluorescent in-Situ Hybridisation (FISH) in Chronic Lymphocytic Leukemia.

Stefan Norin, Mohit Aggarwal, Ann Wallblom, Eva Kimby

Blood (2009) 114 (22): 4218.

https://doi.org/10.1182/blood.V114.22.4218.4218

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C

Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study

Cytogenetic Abnormalities In the Spleen In CLL Patients.

Clonal Evolution During Long-Term Follow-up Using Fluorescent in-Situ Hybridisation (FISH) in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only